Leerink Partnrs Has Bullish Outlook for LXEO FY2026 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Leerink Partnrs increased their FY2026 earnings per share estimates for Lexeo Therapeutics in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($2.54) per share for the year, up from their previous estimate of ($2.55). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ FY2027 earnings at ($2.50) EPS.

LXEO has been the subject of a number of other research reports. Chardan Capital raised their price objective on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Royal Bank of Canada restated an “outperform” rating and set a $24.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday. HC Wainwright upped their price objective on Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Finally, Leerink Partners decreased their target price on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday, November 13th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $23.80.

Lexeo Therapeutics Stock Up 14.5 %

NASDAQ LXEO opened at $5.61 on Friday. The business’s fifty day moving average is $6.71 and its 200-day moving average is $9.31. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a one year low of $4.67 and a one year high of $19.50.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC grew its position in shares of Lexeo Therapeutics by 18.9% in the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock valued at $33,997,000 after purchasing an additional 599,203 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new position in Lexeo Therapeutics in the 3rd quarter worth about $11,307,000. Vestal Point Capital LP grew its holdings in Lexeo Therapeutics by 1.2% during the 3rd quarter. Vestal Point Capital LP now owns 850,000 shares of the company’s stock valued at $7,684,000 after buying an additional 10,000 shares in the last quarter. Verition Fund Management LLC increased its position in shares of Lexeo Therapeutics by 84.5% during the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock valued at $7,027,000 after buying an additional 355,928 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Lexeo Therapeutics by 86.5% in the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock worth $5,003,000 after buying an additional 256,635 shares in the last quarter. Institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.